An update on pharmacotherapeutic strategies for obesity

References

• Hales CM, Fryer CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015-2016. 2017; 288. Cent Dis Control Prevention.
   Google Scholar
• Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440–2450.
   PubMed Web of Science ®Google Scholar
• Mechanick JI, Hurley DL, Garvey WT. Adiposity-based chronic disease as a new diagnostic term: the American Association of Clinical Endocrinologists and American College of Endocrinology position statement. Endocr Pract. 2017 Mar;23(3):372–378.
   PubMed Web of Science ®Google Scholar
• González-Muniesa P, Mártinez-González MA, Hu FB, et al. Obesity. Nat Rev Dis Primers. 2017;3:3.
   Web of Science ®Google Scholar
• Schwartz MW, Seeley RJ, Zeltser LM, et al. Obesity pathogenesis: an endocrine society scientific statement. Endocr Rev. 2017 Aug 1;38(4):267–296.
   PubMed Web of Science ®Google Scholar
• Thaler JP, Tschöp MH, Michael W, et al. Obesity is associated with hypothalamic injury in rodents and humans find the latest version: obesity is associated with hypothalamic injury in rodents and humans. J Clin Investig. 2012;122(1):153–162.
   PubMed Web of Science ®Google Scholar
• Jr MG M, Leibel RL, Seeley RJ, et al. Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol Metab. 2010;21(11):643–651.
   PubMed Web of Science ®Google Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the obesity society. Circulation. 2014;129(25 SUPPL. 1):102–138. 2013.
   Web of Science ®Google Scholar
• U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry Developing Product for Weight Management. Division of Drug Information: Rockville, MD; 2007. p. 1–19.
   Google Scholar
• Food and Drug Administration. Meridia: FDA drug safety communication: FDA recommends against the continued use of meridia (sibutramine). Bethesda, MD: Food & Drug Administration (FDA); 2010.
   Google Scholar
• Eisai. Belviq, Belviq XR (lorcaserin) by Eisai: Drug Safety Communication - FDA Requests Withdrawal of Weight-Loss Drug. 2020. Bethesda, MD: Food & Drug Administration (FDA).
   Google Scholar
• Singh AK, Singh R. Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Expert Rev Clin Pharmacol. 2020 Jan;13(1):53–64.
   PubMed Web of Science ®Google Scholar
• Xenical (orlistat) [package insert]. San Francisco, CA: Genentech USA, Inc.; 1999.
   Google Scholar
• Wadden T. Semaglutide 2.4 mg and intensive behavioral therapy in subjects with overweight or obesity (STEP 3) [abstract]. ObesityWeek. 2020.
   Google Scholar
• MedImmune LLC. A multiple-ascending-dose study to evaluate the efficacy, safety, and pharmacokinetics (PK) of MEDI0382 in overweight and obese participants with type 2 diabetes mellitus. Bethesda, MD: National Library of Medicine (US): ClinicalTrials.gov [Internet]; 2019.
   Google Scholar
• Novartis Pharmaceuticals. A study to evaluate the change in weight after 24 weeks treatment with LIK066 in obese or overweight adults. Bethesda, MD: National Library of Medicine (US): ClinicalTrials.gov [Internet]; 2017.
   Google Scholar
• Novartis Pharmaceuticals. Effect of LIK066 on body weight in patients with elevated body mass index. Bethesda, MD: National Library of Medicine (US): ClinicalTrials.gov [Internet]; 2015.
   Google Scholar
• Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998 Jul 18;352(9123):167–172.
   PubMed Web of Science ®Google Scholar
• Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998 Aug;21(8):1288–1294.
   PubMed Web of Science ®Google Scholar
• Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr. 1999 Jun;69(6):1108–1116.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. Jama. 1999 Jan 20;281(3):235–242.
   PubMed Web of Science ®Google Scholar
• Hauptman J, Lucas C, Boldrin MN, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000 Feb;9(2):160–167.
   PubMedGoogle Scholar
• Rössner S, Sjöström L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity: European Orlistat Obesity Study Group. Obes Res. 2000 Jan;8(1):49–61.
   PubMedGoogle Scholar
• Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002 Jul;25(7):1123–1128.
   PubMed Web of Science ®Google Scholar
• Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2002 Jun;25(6):1033–1041.
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004 Jan;27(1):155–161.
   PubMed Web of Science ®Google Scholar
• Berne C. Orlistat Swedish Type 2 Diabetes Study Group. A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin. Diabet Med. 2005 May;22(5):612–618.
   PubMed Web of Science ®Google Scholar
• Qsymia (phentermine and topiramate extended-release) [package insert]. Winchester, KY: VIVUS Inc.; 2012.
   Google Scholar
• Samanin R, Garattini S. Neurochemical mechanism of action of anorectic drugs. Pharmacol Toxicol. 1993 Aug;73(2):63–68.
   PubMedGoogle Scholar
• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Apr 16;377(9774):1341–1352.
   PubMed Web of Science ®Google Scholar
• Vong L, Ye C, Yang Z, et al. Leptin action on GABAergic neurons prevents obesity and reduces inhibitory tone to POMC neurons. Neuron. 2011;71(1):142–154.
   PubMed Web of Science ®Google Scholar
• Lorello C, Goldfield GS, Doucet E. Methylphenidate hydrochloride increases energy expenditure in healthy adults. Obesity (Silver Spring). 2008 Feb;16(2):470–472.
   PubMed Web of Science ®Google Scholar
• Aronne LJ, Wadden TA, Peterson C, et al. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults (EQUATE). Obesity (Silver Spring). 2013 Nov;21(11):2163–2171.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012 Feb;95(2):297–308.
   PubMed Web of Science ®Google Scholar
• Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012 Feb;20(2):330–342.
   PubMed Web of Science ®Google Scholar
• Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010 Aug 21;376(9741):595–605.
   PubMed Web of Science ®Google Scholar
• Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring). 2009 Jan;17(1):30–39.
   PubMed Web of Science ®Google Scholar
• Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013 May;21(5):935–943.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011 Jan;19(1):110–120.
   PubMed Web of Science ®Google Scholar
• Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes (COR-Diabetes). Diabetes Care. 2013 Dec;36(12):4022–4029.
   PubMed Web of Science ®Google Scholar
• Van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes. 2014;38(6):784–793.
   Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013 Nov;37(11):1443–1451.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687–699.
   PubMed Web of Science ®Google Scholar
• Le Roux CW, Astrup AV, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk Reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399–1409.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Tronieri JS, Sugimoto D, et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. Obesity (Silver Spring). 2020 Mar;28(3):529–536.
   PubMed Web of Science ®Google Scholar
• Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2017 Jul 1;74(7):719–728.
   PubMed Web of Science ®Google Scholar
• Svensson CK, Larsen JR, Vedtofte L, et al. One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients. Acta Psychiatr Scand. 2019 Jan;139(1):26–36.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016 Jul 28;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Legro RS, Dodson WC, Kris-Etherton PM, et al. Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015 Nov;100(11):4048–4058.
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AF, D’Angelo A, et al. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. J Clin Pharm Ther. 2012 Apr;37(2):187–195.
   PubMed Web of Science ®Google Scholar
• Winslow DH, Bowden CH, DiDonato KP, et al. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep. 2012 Nov;35(11):1529–1539.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Ryan DH, Bohannon NJ, et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014 Dec;37(12):3309–3316.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. Jama. 2016 Mar;315(10):990–1004.
   PubMed Web of Science ®Google Scholar
• Orexigen Therapeutics Inc. Naltrexone/bupropion cardiovascular outcomes study. Bethesda, MD: National Library of Medicine. US: ClinicalTrials.gov [Internet]; 2015.
   Google Scholar
• Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016 Feb 13;387(10019):679–690.
   PubMed Web of Science ®Google Scholar
• Khoo J, Hsiang J, Taneja R, et al. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: a pilot randomized trial. Diabetes Obes Metab. 2017 Dec;19(12):1814–1817.
   PubMed Web of Science ®Google Scholar
• Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int J Obes (Lond). 2016 08; 40(8): 1310–1319.
   PubMed Web of Science ®Google Scholar
• Nylander M, Frøssing S, Clausen HV, et al. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online. 2017 Jul;35(1):121–127.
   PubMed Web of Science ®Google Scholar
• Dubé MC, D’Amours M, Weisnagel SJ. Beyond glycaemic control: a cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes. Diabetes Obes Metab. 2018 Jan;20(1):178–184.
   PubMed Web of Science ®Google Scholar
• Dejgaard TF, Frandsen CS, Hansen TS, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2016 Mar;4(3):221–232.
   PubMed Web of Science ®Google Scholar
• O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018 Aug 25;392(10148):637–649.
   PubMed Web of Science ®Google Scholar
• Novo Nordisk A/S. STEP 1: research study investigating how well semaglutide works in people suffering from overweight or obesity (STEP 1). . Bethesda, MD: National Library of Medicine (US): ClinicalTrials.gov [Internet]; 2018.
   Google Scholar
• Novo Nordisk A/S. Research study investigating how well semaglutide works in people with type 2 diabetes suffering from overweight or obesity. Bethesda, MD: National Library of Medicine (US): ClinicalTrials.gov [Internet]; 2018.
   Google Scholar
• Novo Nordisk A/S. Research study to look at how well semaglutide is at lowering weight when taken together with an intensive lifestyle program. Bethesda, MD: National Library of Medicine (US): ClinicalTrials.gov [Internet]; 2018.
   Google Scholar
• Novo Nordisk A/S. Research study investigating how well semaglutide works in people suffering from overweight or obesity. Bethesda, MD: National Library of Medicine (US): ClinicalTrials.gov [Internet]; 2018.
   Google Scholar
• Novo Nordisk A/S. Two-year research study investigating how well semaglutide works in people suffering from overweight or obesity. Bethesda, MD: National Library of Medicine (US): ClinicalTrials.gov [Internet]; 2018.
   Google Scholar
• Novo Nordisk A/S. STEP 6: research study investigating how well semaglutide works in people living with overweight or obesity. Bethesda, MD: National Library of Medicine (US): ClinicalTrials.gov [Internet]; 2019.
   Google Scholar
• Novo Nordisk A/S. Research study of how well semaglutide works in people living with overweight or obesity. Bethesda, MD: National Library of Medicine (US): ClinicalTrials.gov [Internet]; 2020.
   Google Scholar
• Novo Nordisk A/S. Research study to investigate how well semaglutide works compared to liraglutide in people living with overweight or obesity. Bethesda, MD: National Library of Medicine (US): ClinicalTrials.gov [Internet]; 2019.
   Google Scholar
• Novo Nordisk A/S. Semaglutide effects on heart disease and stroke in patients with overweight or obesity. Bethesda, MD: National Library of Medicine (US): ClinicalTrials.gov [Internet]; 2018.
   Google Scholar
• Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020 Sep;5(17):17.
   Web of Science ®Google Scholar
• Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018 11;392(10160):2180–2193.
   PubMed Web of Science ®Google Scholar
• Frias JP, Nauck MA, Van J, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020 Jun;22(6):938–946. .
   PubMed Web of Science ®Google Scholar
• Lilly E. A study of tirzepatide (ly3298176) in participants with obesity or overweight. Bethesda, MD: National Library of Medicine (US): ClinicalTrials.gov [Internet]; 2019.
   Google Scholar
• Ambery P, Parker VE, Stumvoll M, et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018 06; 391(10140): 2607–2618.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. A study to evaluate the efficacy and safety of MEDI0382 in the treatment of overweight and obese subjects with type 2 diabetes. Bethesda, MD: National Library of Medicine (US): ClinicalTrials.gov [Internet]; 2017.
   Google Scholar
• He YL, Haynes W, Meyers CD, et al. The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes. Diabetes Obes Metab. 2019 06;21(6):1311–1321.
   PubMed Web of Science ®Google Scholar
• Bays HE, Kozlovski P, Shao Q, et al. Licogliflozin, a novel SGLT1 and 2 inhibitor: body Weight Effects in a randomized trial in adults with overweight or obesity. Obesity (Silver Spring). 2020 05;28(5):870–881.
   PubMed Web of Science ®Google Scholar
• Yokote K, Sano M, Tsumiyama I, et al. Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity. Diabetes Obes Metab. 2020 Jul;22(7):1102–1110.
   PubMed Web of Science ®Google Scholar
• Lach-Trifilieff E, Minetti GC, Sheppard K, et al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014 Feb;34(4):606–618.
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals. Safety, pharmacokinetics and efficacy of bimagrumab in overweight and obese patients with type 2 diabetes. Bethesda, MD: National Library of Medicine (US): ClinicalTrials.gov [Internet]; 2020.
   Google Scholar
• Clément K, Biebermann H, Farooqi IS, et al. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat Med. 2018 05; 24(5): 551–555.
   PubMed Web of Science ®Google Scholar
• Kuhnen P, Clement K, Wiegand S, et al. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N Engl J Med. 2016 Jul 21;375(3):240–246.
   PubMed Web of Science ®Google Scholar
• FDA approves first treatment for weight management for people with certain rare genetic conditions [Internet]. https://www.fda.gov: U.S. Food and Drug Administration; 2020 [cited 2020 Sep 9]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-first-treatment-weight-management-people-certain-rare-genetic-conditions
   Google Scholar
• Wadden TA, Sternberg JA, Letizia KA, et al. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective. Int J Obes. 1989;13(Suppl 2):39–46.
   PubMed Web of Science ®Google Scholar
• Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011 Oct 27;365(17):1597–1604.
   PubMed Web of Science ®Google Scholar
• Fothergill E, Guo J, Howard L, et al. Persistent metabolic adaptation 6 years after “The biggest loser” competition. Obesity (Silver Spring). 2016 Aug;24(8):1612–1619.
   PubMed Web of Science ®Google Scholar
• Korner J, Aronne LJ. The emerging science of body weight regulation and its impact on obesity treatment. J Clin Invest. 2003 Mar;111(5):565–570.
   PubMed Web of Science ®Google Scholar
• Contrave (naltrexone HCl and bupropion HCl) [package insert]. San Diego, CA: Nalpropion Pharmaceuticals, Inc.; 2014.
   Google Scholar
• Saxenda (liraglutide 3.0mg) [package insert]. Plainsboro, NJ: Novo Nordisk; 2014.
   Google Scholar
• Umashanker D, Shukla AP, Saunders KH, et al. Is obesity the new hypertension? Parallels in the evolution of obesity and hypertension as recognized disease states. Curr Atheroscler Rep. 2017 Aug;19(8):35.
   PubMed Web of Science ®Google Scholar
• Zoss I, Piec G, Horber FF. Impact of orlistat therapy on weight reduction in morbidly obese patients after implantation of the Swedish adjustable gastric band. Obes Surg. 2002 Feb;12(1):113–117.
   PubMed Web of Science ®Google Scholar
• Schwartz J, Chaudhry UI, Suzo A, et al. Pharmacotherapy in conjunction with a diet and exercise program for the treatment of weight recidivism or weight loss plateau post-bariatric surgery: a retrospective review. Obes Surg. 2016 Feb;26(2):452–458.
   PubMed Web of Science ®Google Scholar
• Stanford FC, Toth AT, Shukla AP, et al. Weight loss medications in older adults after bariatric surgery for weight regain or inadequate weight loss: a multicenter study. Bariatr Surg Pract Patient Care. 2018 Dec 1;13(4):171–178.
   PubMed Web of Science ®Google Scholar
• De Silva VA, Suraweera C, Ratnatunga SS, et al. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016 Oct 3;16(1):341.
   PubMedGoogle Scholar
• Goodwin PJ, Chlebowski RT. Obesity and cancer: insights for clinicians. J Clin Oncol. 2016 Dec 10;34(35):4197–4202.
   PubMed Web of Science ®Google Scholar
• Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013 Mar;273(3):219–234.
   PubMed Web of Science ®Google Scholar
• Apolzan JW, Venditti EM, Edelstein SL, et al. Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program (DPP) Outcomes Study (DPPOS). Ann Intern Med. 2019 May 21;170(10):682–690.
   PubMed Web of Science ®Google Scholar
• Chukir T, Mandel L, Tchang BG, et al. Metformin-induced weight loss in patients with or without type 2 diabetes/prediabetes: a retrospective cohort study. Obes Res Clin Pract. 2021;15(1):64-68.
   PubMed Web of Science ®Google Scholar
• Acosta A, Camilleri M, Shin A, et al. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy. Gastroenterology. 2015 Mar;148(3):537–546 e4.
   PubMed Web of Science ®Google Scholar
• Acosta A. Phenotype-guided compare to standard use of pharmacothrapy enhances 1 year weight loss in obesity [abstract]. ObesityWeek. 2020.
   Google Scholar
• Novo Nordisk A/S. A research study of how NNC0174–0833 taken with semaglutide works in people who are overweight or obese. 7/26/2018 ed. Bethesda, MD: National Library of Medicine; 2020.
   Google Scholar